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Background
Despite advances in chemotherapy, the prognosis of relapsed acute lymphoblastic leuke-
mia (ALL) remains poor. Few studies on relapsed ALL have reported the importance of 
intensive consolidation followed with or without allogeneic hematopoietic stem cell 
transplantation (HSCT). 
Methods
We evaluated the post-relapse outcomes in 47 Korean children with a first marrow relapse, 
and analyzed the prognostic factors.
Results
A second complete remission (CR) was achieved in 40 patients (85.1%), and at the time 
of this study, second CR was maintained in 12 of these patients. The estimated 3-yr 
event-free survival (EFS) rate after the first marrow relapse was 29.8±6.7%, and the overall 
survival (OS) rate was 45.3±7.5%. We found that second remission, consolidation of pe-
diatric oncology group chemotherapy regimen (POG 9411), and HSCT significantly af-
fected the outcome of the disease after relapse (P＜0.001; P=0.004; P=0.05).
Conclusion
The results of our study revealed that an intensified POG 9411 consolidation chemo-
therapy regimen followed by HSCT can improve the outcome of patients with relapsed 
ALL. 
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INTRODUCTION
  Although the cure rate of childhood acute lymphoblastic 
leukemia (ALL) has remarkably improved with advances 
in chemotherapy, relapse still occurs in about 30% of the 
cases, with many patients showing relapse in the bone mar-
row (BM) [1, 2]. Although second remission can be achieved 
after intensive reinduction chemotherapy in a majority of 
patients, many patients relapse again and experience a dismal 
outcome [3]. Hematopoietic stem cell transplantation (HSCT) 
is frequently performed to improve the outcome in patients 
with relapsed ALL. In this study, we evaluated the post-re-
lapse outcomes of ALL in 47 Korean children with a first 
marrow relapse, and then analyzed the prognostic factors 
affecting the outcome, with the special focus on consolidation 
therapy and HSCT.
MATERIALS AND METHODS
1. Patients and treatment
  Forty-seven patients (age, ＞1 yr) with an initial diagnosis 
of first BM relapse and without L3 morphology were included 
in this study between 1991 and 2006. Depending on the 
treatment period and the physicians, patients were treated 
with various ALL protocols adapted from the Children’s 
Cancer Group (CCG) [4-9] or the Pediatric Oncology Group 
(POG9411) (Table 1). In addition, 4 patients were treated 
according to the protocol of the Korean multicenter trial 
ALL0603 (Table 2). Allogeneic HSCT has been incorporated 
into intensive, multiagent chemotherapy regimens for the 
treatment of patients with relapsed ALL since 1999, and 
in this study, 10 patients underwent HSCT. Four patients 
received an allogeneic stem cell transplant from a human Korean J Hematol 2010;45:109-14.
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Table 1. POG 9411 treatment schedule.
Induction
Prednisone 40 mg/m
2/day PO in 3 divided doses for 28 days
Vincristine 1.5 mg/m
2(max 2 mg) IV weekly x 4
Doxorubicin 30 mg/m
2/day IV at day 1 and 2
E. coli L-asparaginase
a)  10,000 IU/m
2 IM at days 1, 3, 5, 8, 10, 12,
15, 17, 19, 22, 24, and 26
Triple intrathecal therapy: methotrexate/hydrocortisone/cytarabine
at days 1, 8, and 22
Consolidation I
Ifosfamide 2.8 g/m
2  IV daily for 5 days
Etoposide 100 mg/m
2 IV daily for 5 days
Consolidation II
Cytarabine 1 g/m
2 IV daily for 4 days
Idarubicin
b) 5 mg/m
2 IV daily for 4 days
Course I
Etoposide 100 mg/m
2 IV daily for 3 days
Ifosfamide 3.4 g/m
2 IV daily for 3 days
Course II
6-thioguanine 75 mg/m
2/day PO for 14 days
Methotrexate 25 mg/m
2/dose PO q 6 hours x 4 doses at day 1 
and 8
Triple intrathecal therapy on day 1
Course III
Cytarabine 1 g/m
2 IV daily for 3 days
Idarubicin
c) 5 mg/m
2 IV daily for 3 days
Course IV
Vincristine 2 mg/m
2 (max 2 mg) IV at days 1 and 8
Dexamethasone 8 mg/m
2/day PO in 3 divided doses for 14 days
E. coli L-asparaginase
1 10,000 IU/m
2 IM at days 1, 3, 5, 8, 10, 12,
15, 17
a)We substituted PEG to E-coli L-asparaginase due to Korean 
medical insurance problem. If cumulative dose of anthracylines ≥
450 mg/m
2, 
b)substitute PEG 2,500 IU/m
2/day IM at day 1 and 8 or
E-coli L-asparaginase 10,000 IU/m
2 IM days 1, 3, 5, 8, 10, 12, 15 
and 17, or 
c)discontinue idarubicin.
Table 2. ALL 0603 Induction for marrow relapsed ALL.
Prednisone 60 mg/m
2 orally at days 1-28, then 
taper over 2 weeks
Idarubicin 10 mg/m
2 IV at days 1, 8, 15, and 22 
(give if ANC ＞500/μL, platelet ＞50,000/
μL at days 15,and 22)
Vincristine 1.5 mg/m
2 (max 2 mg) IV at days 1, 8, 15,
and 22
E.coli L-asparaginase 6,000 IU/m
2 IM x 9 doses
Intrathecal therapy Hydrocortisone/cytarabine at days 1, 8, 
and 29
Abbreviation: ANC, absolute neutrophil count.
Table 3. Clinical characteristics of patients.
Characteristics
No. of 
patients
%
Total 　 47 　
Sex Male 33 68.8
　 Female 14 29.2
NCI risk classification 
at diagnosis
Standard risk 28 58.8
High risk 19 39.6
Age at relapse Mean (years) 7.4 　
　 Range 1.5-16.4 　
　　 ＜10 years 36 76.6
　　 ≥10 years 11 23.4
Relapse time  Early 37 77.1
Late 10 20.8
Immunophenotype B  lineage 41 85.4
　 T lineage 6 12.5
Karyotype at relapse Normal 14 29.8 
Hypodiploidy 2 4.3
Hyperdiploidy 9 19.1 
t(9:22) 3 6.4 
t(4:11) 2 4.3 
t(1:19) 1 2.1 
Others 6 12.8 
　 Unknown 10 21.3 
Abbreviation: NCI, national cancer institute.
leukocyte antigen (HLA)-identical sibling donor, and 5 pa-
tients received a stem cell transplant from an unrelated donor; 
1 patient received a stem cell transplant from an HLA-hap-
loidentical related donor. All patients except the patient 
who received the haploidentical transplant were conditioned 
with total body irradiation and cyclophosphamide. The pa-
tient who received the haploidentical transplant was con-
ditioned with a busulfan plus cyclophosphamide regimen.
2. Prognostic factors for treatment outcome 
  The clinical characteristics we examined were: age, sex, 
immunophenotype of leukemic blasts, the National Cancer 
Institute (NCI)’s risk classification (standard risk, 1-9 yr of 
age and WBC count of ＜50,000/μL vs. high risk: others) 
at initial presentation [10], early (＜36 mo from initial diag-
nosis) vs. late (≥36 mo from initial diagnosis) relapse, and 
treatment after relapse. We compared the second remission 
rates of different induction protocols. We compared the 
POG9411 consolidation regimen with other post-remission 
chemotherapies, and analyzed the effect of intensified con-
solidation on survival after the second remission. In addition, 
we analyzed that HSCT could affect the outcome of relapsed 
ALL patients.
3. Statistics
  Complete remission (CR) was defined as less than 5% 
blasts in BM aspirates, and hematologic recovery was defined 
as an absolute neutrophil count of over 1,000/μL and a platelet 
count greater than 100,000/μL. Univariate analyses of the 
association between CR rates and induction chemotherapies 
were performed using the chi-squared test. EFS was defined 
as the time from the first relapse to the next subsequent 
event (relapse, second malignancy, follow-up loss, or death 
from any cause). OS was defined as the time interval between 
the first relapse and death. EFS and OS curves were estimated 
using Kaplan-Meier analysis. Univariate Cox regression anal-
ysis was performed for each potential predictor of outcome. Korean J Hematol 2010;45:109-14.
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Fig. 1. Treatment overview and outcomes for patients with marrow-relapse ALL.
Table 4. Chemotherapies for marrow relapsed patients.
　 No. of patients
Induction protocol
CCG106 10
POG9411 9
ALL0603 4
CCG105 6
CCG106B 6
CCG104 3
CCG1884 4
Miscellaneous 5
Consolidation protocol
POG9411 13
CCG106 9
CCG106B 6
CCG105 4
CCG1884 4
CCG104 3
POG9160 3
Capizzi II 1
Miscellaneous 3
None 1
Relative hazard ratios (HR) with 95% confidence interval 
(CI) were determined for each factor while controlling the 
others. P-value was considered to be significant at ＜0.05. 
All statistical analyses were performed using SPSS, version 
13.0 (SPSS Inc, Chicago, IL). 
RESULTS
1. Patient characteristics
  Forty-seven patients, 33 men and 14 women, were ana-
lyzed as of May 2010. Clinical characteristics of patients 
are shown in Table 3. The follow-up period after relapse 
ranged from 43 mo to 20 yr (median, 145.7 mo). The mean 
age at relapse was 7.4±0.6 yr, with a range of 1.5-16.4 yr. 
The mean time from initial diagnosis to relapse was 17.5±3.2 
mo. Forty-one patients had B cell immunophenotype, and 
6 patients had T cell immunophenotype. According to the 
NCI risk classification, 28 patients were standard risk, and 
19 patients were high risk. Thirty-seven relapses occurred 
within 36 mo from initial diagnosis (early relapse), while 
10 patients relapsed after more than 36 mo from initial diag-
nosis (late relapse).
2. Treatment outcome and prognostic factors
  The overall treatment and outcome data are summarized 
in Fig. 1 and Table 4. Forty patients (85.1%) succeeded in 
attaining second remission, and 7 patients showed persistence 
(M2 or M3 marrow at day 29 of induction). There was no 
significant difference in remission induction rates among 
ALL0603, POG9411, and other induction chemotherapies 
of the past (100% vs. 88.9% vs. 82.4%, P=0.6). After achieving 
second remission, the type of consolidation chemotherapy Korean J Hematol 2010;45:109-14.
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Fig. 2. Event-free survival rates and overall survival rates of patients with marrow-relapse ALL. Event-free survival rates differed due to the 
achievement of second remission (A), consolidation chemotherapy after remission (B), and allogeneic hematopoeitic stem call transplantation 
(HSCT) (C). Overall survival rates were significantly affected by the achievement of second remission (D).
seemed to influence the outcome. Of the 40 patients who 
attained second remission, 12 patients (7 early relapses and 
5 late relapses) were treated with a POG9411 consolidation 
regimen. After the second cycle of POG9411 consolidation, 
7 patients (6 early relapses and 1 late relapse) underwent 
HSCT, and 5 patients continued on chemotherapy only. 
Seven of the 12 patients treated with POG9411 remained 
in a continuous second remission at the time of this study. 
On the other hand, of the 28 patients (25 early relapses 
and 3 late relapses) who received other consolidation regi-
mens, only 3 underwent HSCT, and just 5 remained re-
lapse-free to date. The EFS rate of the POG9411 consolidation 
group was significantly superior to that of the others (53.8± 
13.8% vs. 14.7±6.1%, P=0.004) (Fig. 2).
  The 3-yr EFS rate of marrow relapsed patients was 29.8± 
6.7%, and the 3-yr OS rate was 45.3±7.5%. Univariate analy-
ses of EFS (Table 5) revealed that a second remission, 
POG9411 consolidation, and use of HSCT were significant 
prognostic factors (Fig. 2). Univariate analyses of OS (Table 
5) revealed that achievement of a second remission sig-
nificantly affected outcome (Fig. 1D). In the early-relapsed 
group, EFS rates were significantly altered by HSCT (46.7% 
vs. 13.7%, HR 0.034, 95% CI 0.16-0.93, P=0.034). However, 
HSCT was performed in only 1 late-relapsed patient, so the 
benefit of HSCT for late-relapsed patients was not clear (HR 
0.45, 95% CI 0.05-4.05, P=0.48). Multivariate analysis con-
curred with the results of the univariate analysis. However, 
only a second remission and POG9411 consolidation could 
significantly improve EFS rates (HR 0.17, 95% CI 0.06-0.47, 
P=0.001; HR 0.42, 95% CI 0.17-0.97, P=0.03), and just the 
attainment of remission could affect the OS (HR 0.12, 95% 
CI 0.03-0.39, P＜0.001).
DISCUSSION
  Even with the improvement of chemotherapy, the prog-
nosis of relapsed ALL remained poor. The poor prognosis 
was attributed to lower remission re-induction rates and 
a short duration of the second remission [8, 9]. Previous 
studies have reported that survival after relapse varies sig-
nificantly depending on the time of relapse, sex, NCI risk Korean J Hematol 2010;45:109-14.
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Table 5. Prognostic factors after marrow relapse.
Characteristics 　
Hazard 
ratio
95% CI P
Univariate Cox regression analysis for event-free survival
Sex Male 1.63 0.73-3.63 0.23
　 Female 　　 　
NCI classification Standard risk 0.59 0.29-1.22 0.16
High risk
Age at relapse ≥10 years 1.53 0.67-3.54 0.31
　 <10 years 　　 　
Relapse time Early 1.87 0.77-4.53 0.17
Late
Immuno- B lineage 1.18 0.42-3.37 0.75
phenotype T lineage 　　 　
Remission Remission 0.26 0.11-0.6 0.002
induction Persistence
Consolidation POG9411 0.32 0.31-0.78 0.01
　 Other consolidation 　　 　
HSCT HSCT 0.43 0.17-0.99 0.05
No HSCT
Univariate Cox regression analysis for overall survival
Sex Male 1.84 0.69-4.89 0.23
　 Female 　　 　
NCI classification Standard 0.99 0.45-2.22 0.99
High
Age at relapse ≥10 years 0.99 0.39-2.45 0.98
　 <10 years 　　 　
Relapse time Early 1.17 0.44-3.15 0.75
Late
Immuno- B lineage 0.65 0.22-1.91 0.43
phenotype T lineage 　　 　
Remission Remission 0.2 0.08-0.52 0.001
induction Persistence
Consolidation POG9411 0.71 0.28-1.77 0.46
　 Other consolidation 　　 　
HSCT HSCT 0.75 0.28-1.99 0.56
　 No HSCT 　　 　
Abbreviations: CI, confidence interval; NCI, national cancer in-
stitute; HSCT, hematopoietic stem cell transplantation.
classification at initial diagnosis, and the treatment after 
relapse [11-14]. Our study was limited by the relatively small 
number of patients. Nonetheless, our study suggested that 
intensive consolidation, such as POG9411, and allogeneic 
HSCT were crucial and could improve outcome. 
  Prior experiences have shown that the most important 
factor affecting outcome was the time to relapse [14-16]. 
Although there was not enough statistical significance in 
our study, early-relapsed patients had a shorter second CR 
duration and lower OS rates than those of late-relapsed 
patients. In addition, some studies reported that an initial 
WBC less than 50,000/μL, and age younger than 10 yr at 
initial diagnosis predicted a more favorable outcome after 
relapse [14, 17], while our study failed to show any statistical 
significance of NCI risk classification on post-relapse 
outcome. 
  Attainment of second remission (M1 marrow at day 29 
of re-induction) was a significant prognostic factor for EFS 
and OS. It was an initial step toward a successful outcome, 
and patients who failed to go into remission within 4 weeks 
had a poorer prognosis. In our study, POG9411 consolidation 
therapy significantly increased the EFS rate after second 
remission. The POG9411 protocol was designed to deliver 
very intensive chemotherapy consisting of a modified stand-
ard reinduction combination followed by 2 intensive con-
solidation courses, followed by 4 courses of non-cross re-
sistant drug combinations for continuation therapy. It ap-
peared that POG9411 consolidation helped achieve a greater 
reduction of leukemia. A recent study of CCG1961 indicated 
that longer post-induction intensification failed to prolong 
EFS, while an early aggressive post-induction intensification 
resulted in better EFS and OS for patients with newly diag-
nosed high-risk ALL [18]. Many studies have reported that 
the presence of minimal residual disease (MRD) prior to 
allogeneic transplantation is predictive of subsequent treat-
ment failure [19, 20]. Superior outcome was observed if 
patients received the transplant with less malignant cell bur-
den and lower MRD [21]. The end-induction MRD levels 
are strongly dependent on the intensity of the therapeutic 
regimens [22]. The POG9411 regimen may more effectively 
reduce the MRD as compared to other consolidations in 
this report.
  In addition, HSCT significantly improved EFS rate for 
marrow-relapsed patients. In recent years, HSCT has been 
increasingly utilized in the management of relapsed leuke-
mia. Previously published retrospective studies showed that 
the marrow-relapsed patients that received allogeneic HSCT, 
especially from HLA-matched sibling donors, showed a sig-
nificantly better outcome than the patients that received 
chemotherapy alone [23-26]. However, benefits of HSCT 
in late BM relapse seemed less evident and the late-relapsed 
patients had a considerably better chance of cure by chemo-
therapy alone [12, 26]. Our study also demonstrated that 
HSCT was more beneficial for EFS in early-relapsed patients, 
while there was no clear advantage of HSCT for EFS in 
late-relapsed patients.
  This study showed that POG9411 intensive consolidation 
therapy followed by allogeneic HSCT conferred a better sur-
vival rate in children with ALL with BM relapse. However, 
this retrospective study was limited by a relatively small 
number of patients and multiple heterogeneous treatment 
regimens. Since these patients were treated over a 20-yr 
period, the advancement in therapies and supportive care 
over time may have improved the treatment outcome. There-
fore, a prospective multicenter trial involving a larger num-
ber of patients treated with a uniform regimen is clearly 
required for ALL with BM relapse. We believe that the 
use of an intensive consolidation regimen comprising non- 
cross resistant drug combinations followed by HSCT should 
be an integral part of therapeutic strategy in designing a 
new protocol for the treatment of marrow-relapse ALL in 
children.Korean J Hematol 2010;45:109-14.
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